Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed · Phase 2

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining pentostatin and rituximab in treating patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Key facts

Study ID

NCT00026351

Run by

Pharmatech Oncology

Starts

2000-12-01

Expected to finish

2003-06-01

Last updated by the study team

2013-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cancer and Blood Institute of the Desert — Rancho Mirage, California, United States
• Redding Medical Center — Redding, California, United States
• Oncology-Hematology Associates, P.A. — Clinton, Maryland, United States
• North Shore Hematology/Oncology Associates, P.C. — East Setauket, New York, United States
• Hematology Oncology Associates of Central New York, P.C. — Syracuse, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.